Triptorelin 0.1 mg as a Luteal Phase Support in Antagonist Intracytoplasmic Sperm Injection Cycles

Area of Science:

• Reproductive Endocrinology
• Infertility Treatment
• Assisted Reproductive Technology (ART)

Background:

• Transvaginal progesterone is crucial for luteal phase support in fertility treatments.
• Gonadotrophin-releasing-hormone analogues (GnRHa) may influence steroidogenesis and gonadotropin levels.
• The study investigates the impact of GnRHa combined with progesterone on pregnancy rates.

Purpose of the Study:

• To compare the efficacy of progesterone (P) plus GnRHa versus P alone for luteal phase support.
• To evaluate the effect on clinical pregnancy rates in women undergoing GnRH antagonist cycles.
• To assess the impact on progesterone levels and other key fertility markers.

Main Methods:

• An open-label randomized controlled trial involving 150 women was conducted.
• Participants received either P + GnRHa or P alone for luteal phase support.
• The study utilized an antagonist-controlled ovarian hyperstimulation protocol.

Main Results:

• The group receiving GnRHa and P showed significantly higher progesterone levels and beta-human chorionic gonadotropin (BHCG) levels.
• Improved implantation rates, clinical pregnancy rates, and live birth rates were observed in the GnRHa + P group.
• Significant increases in fetal pulsation, biochemical pregnancy, and ongoing pregnancy rates were noted.

Conclusions:

• Adding GnRHa to progesterone as luteal phase support significantly enhances fertility outcomes.
• This combined approach leads to superior progesterone levels, implantation, and pregnancy rates.
• GnRHa combined with progesterone represents a promising strategy for improving ART success.